# LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

> **NCT05886439** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** LK101 injection (personlized neoantigen pulsed DC vaccine )
- **DRUG:** Pembrolizumab
- **DRUG:** Durvalumab
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05886439
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-11
- **Primary completion:** 2027-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886439, "LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05886439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*